Abstract
Object: The aim of the present study was whether a combination of Pentosidine and carboxy-terminal telopeptide of type I collagen (I-CTP) can reliably risk stratify patients with preserved LV ejection fraction. Methods and Results: Serum levels of pentosidine and I-CTP were measured at admission in 150 consecutive patients hospitalized for chronic heart failure (CHF). Patients were divided into 2 groups based on the LV ejection fraction (LVEF): reduced LV systolic function group (LVEF < 50%, n = 67) and preserved LVEF group (LVEF > 50%, n = 83).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
